AACR 2021 | Enhancing cell-free DNA mutation detection with novel liquid-phase extraction

Filip Janku • 10 Apr 2021

AACR 2021

In early-stage cancer diagnostics, low yields of extracted cell-free DNA (cfDNA) from plasma have hindered the development of liquid biopsies in this patient population. Filip Janku, MD, PhD, MD Anderson Cancer Center, TX, discusses the development of a liquid-phase-based DNA extraction method that enriches for cfDNA. This approach provides improved cfDNA mutation detection by increasing cfDNA recovery and reducing contaminating genomic DNA background. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

Disclosures

Filip Janku, MD, PhD, has received research support from Novartis, Genentech, BioMed Valley Discoveries, Astellas, Astex, Agios, Bicara, Bioxcel Therapeutics, Plexxikon, Deciphera, Piqur, Symphogen, Bristol-Myers Squibb, Asana, Merck, Ideaya Biosciences, JS Innophram, Synthorx, Sanofi, SpringBank Pharmaceuticals, SQZ Biotechnologies, Synlogic, FujiFilm Pharmaceuticals, Sotio, Lilly, Puretech Health and Novellus; is or has been on the Scientific Advisory Boards for Bicara, Illumina, Ideaya Biosciences, IFM Therapeutics, Synlogic, Sotio, Puretech Health, Petra Pharma, Novellus and Deciphera; is a paid consultant for Cardiff Oncology and Immunomet; and has ownership interests in Cardiff Oncology.